Tomas Kiselak
10% Owner; Director; Director, 10% Owner · 14 filings · Latest: Aug 7, 2026
Apogee Therapeutics, Inc.
CRESCENT BIOPHARMA, INC.
Damora Therapeutics, Inc.
Galecto, Inc.
Jade Biosciences, Inc.
Oruka Therapeutics, Inc.
Spyre Therapeutics, Inc.
Viridian Therapeutics, Inc.\DE
Zenas BioPharma, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
APGE | Tomas Kiselak | Director | Aug 7, 2026 | Option Exercise | $23.60 | 42,208 | $996.0K | 340,855 | |
CBIO | Tomas Kiselak | Director, 10% Owner | Jul 16, 2026 | Purchase | $14.50 | 853,450 | $12.4M | 3,601,316 | |
ORKA | Tomas Kiselak | Director, 10% Owner | Jul 1, 2026 | Sale | $84.43 | 3,553,410 | $300.0M | 1,131,954 | |
SYRE | Tomas Kiselak | Director | Jun 23, 2026 | Sale | $85.31 | 4,684,781 | $399.7M | 0 | |
ZBIO | Tomas Kiselak | Director | Mar 31, 2026 | Purchase | $20.00 | 150,000 | $3.0M | 2,359,025 | |
GLTO | Tomas Kiselak | 10% Owner | Feb 9, 2026 | Option Exercise | $0.00 | 8,713,000 | — | 2,904,000 | |
APGE | Tomas Kiselak | Director | Jan 22, 2026 | Sale | $76.30 | 1,750,000 | $133.5M | 298,647 |